Dosing & Uses
Acute Bacterial Skin and Skin Structure Infections
Pending FDA approval for treatment of acute bacterial skin and skin structure infections (ABSSSI)
Next:
Pharmacology
Mechanism of Action
Antibiotic; dihydrofolate reductase Inhibitor with a low propensity for resistance development and rapidly bactericidal in vitro
Inhibition of dihydrofolate reductase, inhibits folic acid reduction to tetrahydrofolate, causing inhibition of microorganism growth
Targeted spectrum of activity against Gram-positive bacteria, including MRSA
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.